Citadel Advisors LLC boosted its position in Orthofix International N.V. (NASDAQ:OFIX) by 83.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,313 shares of the medical device company’s stock after acquiring an additional 5,138 shares during the period. Citadel Advisors LLC owned 0.06% of Orthofix International worth $535,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in OFIX. Bank of America Corp DE grew its holdings in Orthofix International by 834.2% in the 1st quarter. Bank of America Corp DE now owns 28,838 shares of the medical device company’s stock worth $1,100,000 after acquiring an additional 25,751 shares during the last quarter. State Street Corp boosted its stake in shares of Orthofix International by 27.0% during the 1st quarter. State Street Corp now owns 462,479 shares of the medical device company’s stock valued at $17,640,000 after purchasing an additional 98,212 shares in the last quarter. Aperio Group LLC boosted its stake in shares of Orthofix International by 23.4% during the 2nd quarter. Aperio Group LLC now owns 15,316 shares of the medical device company’s stock valued at $712,000 after purchasing an additional 2,902 shares in the last quarter. Municipal Employees Retirement System of Michigan bought a new stake in shares of Orthofix International during the 2nd quarter valued at about $196,000. Finally, Texas Permanent School Fund boosted its stake in shares of Orthofix International by 41.5% during the 2nd quarter. Texas Permanent School Fund now owns 13,174 shares of the medical device company’s stock valued at $612,000 after purchasing an additional 3,867 shares in the last quarter. 94.61% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Brad Mason sold 5,000 shares of Orthofix International stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total transaction of $267,400.00. Following the completion of the transaction, the chief executive officer now directly owns 183,053 shares of the company’s stock, valued at approximately $9,789,674.44. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Luke T. Faulstick sold 4,800 shares of Orthofix International stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $51.22, for a total transaction of $245,856.00. Following the transaction, the director now directly owns 7,729 shares of the company’s stock, valued at $395,879.38. The disclosure for this sale can be found here. Company insiders own 5.60% of the company’s stock.

A number of brokerages have recently weighed in on OFIX. BidaskClub raised shares of Orthofix International from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Zacks Investment Research raised shares of Orthofix International from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a research note on Thursday, November 2nd. BTIG Research set a $56.00 target price on shares of Orthofix International and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, TheStreet lowered shares of Orthofix International from a “b” rating to a “c+” rating in a research note on Tuesday, October 31st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $54.42.

Orthofix International N.V. (NASDAQ OFIX) opened at $51.94 on Tuesday. Orthofix International N.V. has a 12-month low of $32.51 and a 12-month high of $54.73. The stock has a market cap of $963.51, a PE ratio of 34.54, a P/E/G ratio of 2.62 and a beta of 0.14.

Orthofix International (NASDAQ:OFIX) last issued its quarterly earnings results on Monday, October 30th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Orthofix International had a net margin of 0.33% and a return on equity of 10.26%. The company had revenue of $105.30 million during the quarter, compared to analysts’ expectations of $100.67 million. During the same period last year, the company posted $0.36 EPS. Orthofix International’s revenue was up 6.9% on a year-over-year basis. analysts anticipate that Orthofix International N.V. will post 1.61 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Orthofix International N.V. (OFIX) Holdings Raised by Citadel Advisors LLC” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/12/orthofix-international-n-v-ofix-holdings-raised-by-citadel-advisors-llc.html.

Orthofix International Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix International N.V. (NASDAQ:OFIX).

Institutional Ownership by Quarter for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.